Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method.
Diabetologia 54, 699-700 (2011)
Autoantibodies are a hallmark feature of type 1 diabetes and have proved useful markers for disease prediction and classification [1]. New autoantibodies are of interest since they may strengthen disease relevance in autoantibody-positive individuals [2, 3]. Recently, autoantibodies against the inducible chemokine CCL3 were reported to be associated with type 1 diabetes [4], and commercial kits for the measurement of anti-CCL3 autoantibodies are now available. CCL3 is produced during inflammation and is suggested to be produced by beta cells under stress. We had the opportunity to evaluate this commercial kit and here report our findings. Sera from patients with new or recent onset of type 1 diabetes (n = 54; median age 10 years; IQR 7.5–13.5 years), controls (n = 40; median age 11.2 years; IQR 4.7–16.3 years), first-degree relatives of patients with type 1 diabetes (n = 33; median age 10.5 years; IQR 7.7–11.2 years) and participants with other autoimmune diseases (n = 17; median age 1
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Autoantibody; CCL3; ELISA; Type 1 diabetes
ISSN (print) / ISBN
0012-186X
e-ISSN
1432-0428
Journal
Diabetologia
Quellenangaben
Volume: 54,
Issue: 3,
Pages: 699-700
Publisher
Springer
Publishing Place
Berlin ; Heidelberg [u.a.]
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes Research (IDF)
Institute of Pancreatic Islet Research (IPI)
Institute of Pancreatic Islet Research (IPI)